Introduction
============

The concept of "One Health," which is the integration of human, animal, environmental, and ecosystem health, has recently emerged ([@B29]). One issue that should be addressed through a One Health approach is antimicrobial resistance (AMR). Therefore, we need to take steps to address the dissemination of AMR through the adoption of a One Health approach, promoting the integration of human and animal health, food safety, and environmental surveillance ([@B23]; [@B25]).

*Enterobacteriaceae* are among the most commonly reported causes of bacterial infections in humans and animals ([@B24]). Notably, *Enterobacteriaceae* carrying extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases (AmpCs) are broadly distributed among extended-spectrum cephalosporin (ESC)-resistant bacteria ([@B11]). In both humans and animals, CTX-M-type enzymes are the most common ESBLs, whereas CMY-, and DHA-type enzymes are the most prevalent plasmid-mediated AmpCs ([@B17]; [@B9]; [@B18]). These enzymes are able to inactivate ESCs and are normally encoded on mobile genetic elements, thus they can be transmitted to the same or different bacteria in humans, animals, foods, or the environment through either directly (transmission of AMR bacteria), or indirectly (transfer of AMR genes) ([@B7]; [@B8]). Companion animals could play a role as a reservoir of AMR bacteria, as they are in close association with humans, living in their homes, and near their food. In addition, the widespread use and misuse of antibiotics in both human and veterinary medicine is increasing the spread of AMR bacteria ([@B4]; [@B19]; [@B21]). However, the impact of companion animals on human health in terms of attributing to exchange and share AMR determinant is not yet clear. Therefore, systematic control and prevention, through implementation of a national AMR surveillance program, are greatly needed and should be applied in the fields of human, and veterinary clinical medicine.

In this study, we represented a molecular characterization of ESC-resistant *Enterobacteriaceae* isolates collected from companion animals, humans, and veterinary hospital environments as part of a national surveillance program at 36 veterinary hospitals in South Korea and examined their epidemiological relatedness.

Materials and Methods
=====================

Bacterial Profiles
------------------

We collected *Escherichia coli* and *Klebsiella pneumoniae* isolates from the rectal swabs of companion animals, including dogs (*n* = 315) and cats (*n* = 74); stool samples of humans, including pet owners (*n* = 48) and medical staff (*n* = 33); and 352 swabs of veterinary hospital environmental surfaced, including examination tables, cages, water bowls, scales, microscopes, keyboards, and switches, at 36 veterinarian hospitals of various regions in South Korea during July to November, 2017. All samples were cultured on CHROMagar ESBL (CHROMagar, Paris, France) for use in the selection of *E. coli* (dark pink to reddish colony) and *Klebsiella*/*Enterobacter*/*Citrobacter* species (metallic blue colony). After pure sub-culture for a single colony on each blood agar plate (SPL Life Sciences, Gyeonggi-do, South Korea) per a given sample, *E. coli* and *K. pneumoniae* isolates were selected and identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) with a Vitek-MS (bioMérieux, Marcy-l'Etoile, France).

Antimicrobial Susceptibility Testing
------------------------------------

The isolates were tested for antimicrobial susceptibility to the following antimicrobial agents: ampicillin, piperacillin, ampicillin-sulbactam, cefazolin, cefoxitin, cefotaxime, ceftazidime, cefepime, aztreonam, ertapenem, imipenem, meropenem, amikacin, gentamicin, ciprofloxacin, and trimethoprim-sulfamethoxazole, by the agar disk diffusion method on Mueller-Hinton agar (Difco Laboratories, Detroit, MI, United States) according to the guidelines of the Clinical and Laboratory Standards Institute ([@B2]). The minimal inhibitory concentration of colistin was determined by broth microdilution using the criteria of the European Committee for Antimicrobial Susceptibility Testing ([@B5]).

Detection of Antimicrobial Resistance Genes
-------------------------------------------

Template DNA was prepared by the boiling method. PCR and DNA sequencing of various AMR genes, including *bla*~CTX--M--1\ group~, *bla*~CTX--M--2\ group~, *bla*~CTX--M--9\ group~, *bla*~CTX--M--25\ group~, *bla*~TEM~, *bla*~SHV~, *bla*~DHA~, *bla*~CMY--1~, *bla*~CMY--2~, *bla*~ACC~, *bla*~ACT~, *bla*~FOX~, *bla*~IMP~, *bla*~VIM~, *bla*~NDM~, *bla*~KPC~, *bla*~GES~, and *bla*~OXA--48--like~, were performed as described previously ([@B14]). The sequences were compared to published DNA sequences using BLAST^[1](#footnote1){ref-type="fn"}^.

ESBL/AmpC Production Phenotypic Testing
---------------------------------------

ESC-resistant isolates with ESBL/AmpC PCR-negative were performed phenotypic disk diffusion test to confirm for ESBL/AmpC production ([@B27], [@B28]).

Nucleotide Sequence-Based Bacterial Typing
------------------------------------------

The epidemiological relationships among the CTX-M-type or/and CMY-2-like-producing isolates, which being collected from humans, companion animals, and the environment, were analyzed by pulsed-field gel electrophoresis (PFGE) using *Xba*I restriction enzyme. Then after, multilocus sequence typing (MLST) was performed for *E. coli* and *K. pneumoniae* strains with representative PFGE profiles as described previously ([@B20]; [@B10]). *E. coli* ATCC 25922 and *K. pneumoniae* ATCC 13883 were included as quality controls.

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS Statistics version 24.0.0 (IBM Corp., Armonk, NY, United States). For comparison of the ESC-resistance rates between groups, we used the chi-square test. All *p* values were two-sided, and values less than 0.05 were considered statistically significant.

Results
=======

ESC Resistance and Antimicrobial Susceptibility
-----------------------------------------------

Among 389 samples of companion animals (315 dogs and 74 cats), 81 of humans (48 owners and 33 staffs), and 352 of veterinary hospital environmental surface, a total of 236 non-duplicated ESC-resistant isolates, including 195 *E. coli*, and 41 *K. pneumoniae* isolates were recovered. There were some cases that both ESC-resistant *E. coli* and *K. pneumoniae* isolates were simultaneously selected from 17 dogs, one cat, and one the environmental sample ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}). Of the 195 ESC-resistant *E. coli* isolates, 174 (44.7%) were recovered from companion animals (389 total samples), 14 (17.3%) were recovered from human stool samples (81 total samples), and 7 (2%) were recovered from the environment (352 total samples). Among the *E. coli* isolates from companion animals, the ESC-resistance rate for canines (49.2%) was significantly higher than the rate for feline isolates (25.7%) (*p* value = \<0.001). Of the 41 ESC-resistant *K. pneumoniae* isolates, 29 (7.5%) were recovered from companion animals, and 12 (3.4%) were recovered from the environment. Among the *K. pneumoniae* isolates from companion animals, the ESC-resistance rate for canines (8.3%) was not statistically different from the rate of felines (4.1%) (*p* value = 0.216). None were recovered from human-derived samples ([Table 1](#T1){ref-type="table"}). The AMR profiles of the ESC-resistant *E. coli* and *K. pneumoniae* isolates are listed in [Supplementary Tables S2](#SM3){ref-type="supplementary-material"}, [S3](#SM4){ref-type="supplementary-material"}, respectively.

###### 

Genotypes of β-lactamases in extended-spectrum cephalosporin-resistant *E. coli* and *K. pneumoniae* isolates from companion animals, humans, and the hospital environment.

  **Organism**      **ESC resistance gene^a^**   **No. (%) isolates**                                                              
  ----------------- ---------------------------- ------------------------- -------------- ----------- ---------- ------------ ---- ----
  *E. coli*         CTX-M-1                                                               3           1          0            0    4
                    CTX-M-3                                                               4           0          0            1    5
                    CTX-M-15                                                              11          1          4            0    16
                    CTX-M-15                     CMY-2-like                NDM-5          4           0          0            0    4
                    CTX-M-55                                                              26          1          0            0    27
                    CTX-M-55 + CTX-M-14                                                   0           1          0            0    1
                    CTX-M-55                     CMY-2-like                               2           0          0            0    2
                    CTX-M-14                                                              25          2          1            1    29
                    CTX-M-14                     CMY-2-like                               1           0          0            0    1
                    CTX-M-14                     DHA-1-like                               1           0          0            0    1
                    CTX-M-24                                                              3           2          0            0    5
                    CTX-M-27                                                              5           1          2            0    8
                    CTX-M-65                                                              6           1          0            0    7
                    SHV-190                                                               1           0          0            0    1
                    CMY-2-like                                             40             6           2          3            51   
                                                 CMY-2-like + DHA-1-like                  0           2          0            0    2
                    CMY-4                                                  1              0           0          0            1    
                                                 DHA-1-like                               3           0          2            0    5
                                                 DHA-9                                    1           0          0            0    1
                    Unidentified                 Unidentified              Unidentified   18          1          3            2    24
                    Total                        155 (49.2)                19 (25.7)      14 (17.3)   7 (2.0)    195 (23.7)        
  *K. pneumoniae*   CTX-M-15                                                              10          1          0            1    12
                    CTX-M-15                     DHA-1-like                               6           0          0            6    12
                    CTX-M-15 + CTX-M-14          DHA-1-like                               1           0          0            0    1
                    CTX-M-55                     DHA-1-like                               0           0          0            1    1
                    CTX-M-55                     DHA-9                                    0           0          0            1    1
                    CTX-M-14                                                              2           0          0            1    3
                    SHV-12                       DHA-1-like                               2           0          0            2    4
                    SHV-26                       DHA-1-like                               2           0          0            0    2
                    SHV-28                                                                1           0          0            0    1
                                                 CMY-2-like                               1           1          0            0    2
                                                 DHA-1-like                               0           1          0            0    1
                                                 CMY-2-like + DHA-1-like                  1           0          0            0    1
                    Total                        26 (8.3)                  3 (4.1)        0 (0)       12 (3.4)   41 (5.0)          

a

ESC, extended-spectrum cephalosporin.

b

ESBL, extended-spectrum β-lactamase.

Genotypes of ESC Resistance
---------------------------

We performed genotype characterization of ESC resistance for all ESC-non-susceptible 195 *E. coli* and 41 *K. pneumoniae* isolates, regardless of isolation of both *E. coli* and *K. pneumoniae* isolates in same sample. Among the ESC-non-susceptible 195 *E. coli*, 171 (87.7%) isolates harbored known ESC resistance genes ([Table 1](#T1){ref-type="table"}), including nine different ESBL types and four AmpC types. A few isolates harbored both ESBL and AmpC (seven isolates carried CTX-M-type and CMY-2-like genes, and one isolate carried CTX-M-type and DHA-1-like genes). Of the 174 ESC-resistant *E. coli* isolates categorized from companion animals, *bla*~CMY--2--like~ gene (*n* = 46, 26.4%) was most common ESC resistance determinant, followed by CTX-M-55 (*n* = 30, 17.2%), CTX-M-14 (*n* = 28, 16.1%), and CTX-M-15 (*n* = 20, 11.5%), which were the dominant ESBL genes. Interestingly, for the ESC-resistant *E. coli* isolates in companion animals, NDM-5 was detected in four isolates along with *bla*~CTX--M--15~ and *bla*~CMY--2--like~. Of the 14 ESC-resistant *E. coli* isolates from humans, CTX-M-15 was predominant, which accounted for 28.6% of the total (*n* = 4). One isolate was positive for SHV-190, and remaining 24 isolates were negative for both known ESBLs and AmpCs by the primers used in this study.

Among the ESC-non-susceptible 41 *K. pneumoniae* isolates, six different ESBL types and three AmpC types were detected in all 41 (100%) isolates ([Table 1](#T1){ref-type="table"}). In samples from companion animals and the environment, CTX-M-15 (*n* = 25) and DHA-1-like (*n* = 21) were dominant genotypes, followed by SHV-types (*n* = 5), and CTX-M-14 (*n* = 5). The presence of both ESBL- and AmpC-type genes was detected in 21 *K. pneumoniae* isolates (51.2%), and in 8 *E. coli* isolates (4.1%). No ESC-resistant *K. pneumoniae* isolates were recovered from human stool samples ([Table 1](#T1){ref-type="table"}).

Macro-Restriction of ESC-Resistant *Enterobacteriaceae*
-------------------------------------------------------

To determine the epidemiological relatedness among ESC-resistant isolates from companion animals, humans, and various hospital areas in veterinarian clinics, 124 *E. coli* and 23 *K. pneumoniae* isolates carrying the predominant ESC resistance genes (*E. coli* carrying CTX-M-15, CTX-M-55, CTX-M-14, or/and CMY-2-like genes, and *K. pneumoniae* carrying CTX-M-15 or/and DHA-1-like genes) were subjected to PFGE analysis. Among the 124 *E. coli* isolates, similar PFGE patterns were observed only between isolates from companion animals and humans ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). Five CMY-2-like harboring *E. coli* isolates without other resistance genes belonged to one pulsotype, with \>85% similarity, which was attributed to sequence type 405 (ST405) by MLST analysis. Three of the five isolates were derived from samples obtained at the same hospital, two were from humans (E246 was from a veterinarian and E249 was from a nurse) and the third was from a rectal swab from a dog (E245) admitted to the above hospital. The two remaining isolates (E92 and E118) were collected from two dogs at different veterinary clinics ([Figure 1](#F1){ref-type="fig"}). For the 23 *K. pneumoniae* isolates that mostly produced CTX-M-15 or/and DHA-1-like enzymes in companion animals and the environment, 7 pulsotypes were identified which corresponded to ST307 (d, e, and f PFGE-types), ST392 (a, b, and c PFGE-types), and ST950 (g PFGE-type) ([Figure 2](#F2){ref-type="fig"}).

![Pulsed-field gel electrophoresis (PFGE) dendrogram of the five CMY-2-like producing *E. coli* ST405 (This image was modified for illustrative purposes). Owner-566 is a veterinarian in the hospital C-26. Staff-570 is a nurse in the hospital C-26. M, metropolitan region; C, central region; S, southern region.](fmicb-10-01371-g001){#F1}

![Epidemiological profiles of 23 *K. pneumoniae* isolates carrying ESC resistance gene (CTX-M-15 and DHA-1-like) determined by PFGE analysis using *Xba*I restriction. Environment-1, examining table; Environment-2, cage; Environment-4, scale; Environment-7, keyboard; Environment-8, switch; M, metropolitan region; C, central region; S, southern region.](fmicb-10-01371-g002){#F2}

Discussion
==========

Antimicrobial resistance surveillance systems of clinical isolates in South Korea have been well-documented in both the Korea antimicrobial resistance monitoring system (KARMS) and Korea global antimicrobial surveillance system ([@B12]; [@B15]). However, this is the first report on the prevalence and molecular characterization of ESC-resistant *Enterobacteriaceae* isolates collected from companion animals, humans, and the veterinarian hospital environment for national surveillance in South Korea. Previously, the KARMS study for human clinical isolates reported that the rate of AMR to cefotaxime was 35.0% in *E. coli* and 41.0% in *K. pneumoniae* ([@B12]). Among the *E. coli* isolates collected from rectal swabs of dogs and cats obtained in this study, the rates of ESBL- or/and AmpC-producing *E. coli* isolates were 43.5% (137/315) for dogs and 24.3% (18/74) for cats, respectively. In previous study showed that the rate of ESBL or/and AmpC-producing *E. coli* isolates in dogs had a 38.1% ([@B26]), which represented currently increasing incidence in South Korea.

CTX-M type ESBL genes in the fields of human medicine, and CMY type AmpC genes in both human and veterinary medicine, are dominant in *E. coli* worldwide including South Korea ([@B11]; [@B14]). Especially, CTX-M-15- and CMY-2-producing *E. coli* isolates are the most frequently detected genotypes associated with ESC resistance in companion animals and humans, respectively ([@B18]; [@B31]; [@B7]; [@B4]). Because companion animals are in close contact with humans, the genotypes of companion animals in this study were initially expected to be similar to the genotypes of humans disseminated in South Korea. The total number of CMY-2-like-producing *E. coli* isolates was greater than the number of CTX-M-type (CTX-M-55-, CTX-M-14, and CTX-M-15)-producing isolates from the rectal swabs of companion animals, which was consistent with the numbers described in previous reports of AmpC in animals, suggesting that it is an important mechanism of resistance to ESC ([@B26]; [@B4]). Instead, CTX-M-15 was more detected than other ESC-resistant determinants in humans, but CTX-M-55 and CTX-M-14 were more prevalent than CTX-M-15 in companion animals in this study. The CTX-M-55 and CTX-M-14 were previously detected in food-producing animals and turkey meat, respectively ([@B13]; [@B22]; [@B18]; [@B16]). These findings indicate that the ESC resistance gene variants are not limited to certain hosts, emphasizing the need for coordinated control in the concept of One Health. In addition, in previous studies, CTX-M-14 were the most common ESC resistance genotypes, whereas CTX-M-55 was rarely detected in companion animals in South Korea ([@B26]; [@B30]). Therefore, the observed increase in CTX-M-55 in companion animals in South Korea may also affect AMR transmission between humans and companion animals.

All 41 ESC-resistant *K. pneumoniae* isolates harbored ESC-resistance genes. In contrast, of the 195 ESC-resistant *E. coli* isolates, 24 (12.3%) isolates did not identify for ESBL, and/or AmpC type in this study. These isolates were susceptible to cefoxitin and were positive for ESBL production (disk diffusion test), suggesting the presence of an ESBL variant not detected by the primers used in this study. We performed PFGE to understand the relatedness between ESC-resistant *E. coli* and *K. pneumoniae* isolates from humans, companion animals, and the environment in veterinary hospitals during 5 months. Most of the ESC-resistant isolates had no evidence of clonal spread between humans and companion animals. Instead, the five CMY-2-producing *E. coli* ST405 isolates from two humans and three dogs showed high identity, which suggested the possibility of direct transmission between humans, and companion animals. The spread of *E. coli* ST405 carrying CTX-M-15 has been frequently described in humans as an epidemic lineage, along with *E. coli* ST131 ([@B3]). However, we detected *E. coli* ST405 carrying CMY-2-like genes in this study.

In this study, CTX-M-15 (61.0%, *n* = 25/41), either alone or in combination with DHA-1-like, was mostly detected in ESC-resistant *K. pneumoniae* isolates from companion animals and the environmental samples. Recently, CTX-M-15- and DHA-1-coproducing *K. pneumoniae* ST11 have emerged in human patients and are being disseminated ([@B1]; [@B14]), while there was no report that described in *K. pneumoniae* isolate carrying CTX-M-15 from dogs and cats in South Korea. CTX-M-15 was essentially associated with ST11, ST15, ST307, and ST392 clones in *K. pneumoniae*, which have been frequently detected in other part of the world ([@B6]; [@B32]). ST307 is also frequent among carbapenemase producers in South Korea, suggesting a wider dissemination in different setting in our country ([@B33], [@B34]). There was no transmission between humans and companion animals, however, clonal spread was observed among companion animals and between companion animals and the environment in this study. Based on the observation of environmental colonization of AMR *K. pneumoniae* in veterinary hospitals, infection control for the environment should be carefully considered in the veterinary field.

Our results have limitations: (i) the number of stool specimens from humans was less than that of companion animals and the isolation of ESBL/AmpC producing *K. pneumoniae* was unusually more frequent than *E. coli* with ESBL/AmpC in the environmental samples. Unfortunately, we do not know the reason why for this, (ii) plasmid distribution was not included in this study, which is well known to contribute to ESBL distribution in *Enterbacteriaceae*. Nevertheless, our findings illustrate the importance of infection control strategies for usage of antibiotics and demonstrate the need for further cooperation among the fields of human and veterinary medicine and environmental science in the One Health perspective.
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###### 

Epidemiological profiles of 124 ESBL/AmpC (CTX-M-15, CTX-M-55, CTX-M-14, or/and CMY-2-like) producing *E. coli* isolates from humans, companion animals (green box), and the environment (blue box) determined by PFGE analysis using XbaI restriction. Red box represented five CMY-2-like producing *E. coli* isolates related closely. *E. coli* ATCC strain used in this study was *E. coli* ATCC 25922.

###### 

Click here for additional data file.

###### 

Samples that grew both *E. coli* and *K. pneumoniae* isolates from dog, cat, and the environment.
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Click here for additional data file.

###### 

Antimicrobial susceptibilities of extended-spectrum cephalosporin-resistant *E. coli* isolates from humans, companion animals, and the hospital environment.
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Click here for additional data file.

###### 

Antimicrobial susceptibilities of extended-spectrum cephalosporin-resistant *K. pneumoniae* isolates from companion animals and the hospital environment.
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Click here for additional data file.
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